{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["cabozantinib","nivolumab"]],"indication":"advanced or metastatic non-clear cell renal cell carcinoma","name":"NCT03635892","nct_id":"NCT03635892","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03635892. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Cohort 1 is designed as a single stage study with a total sample size of 20. This design discriminates between ORR rates of 10 and 35%.","label":"Cohort 1: Unclassified, papillary, and HL RCC","type":"EXPERIMENTAL"},{"description":"Cohort 2 is designed as a Simon's optimal two-stage design with a total possible sample size of 17. This design discriminates between ORR rates of 5 and 25%.","label":"Cohort 2: Chromophobe RCC","type":"EXPERIMENTAL"},{"description":"Cohort 3 is designed as an expansion cohort of Cohort 1 with 20 additional patients to obtain a more precise estimate of the ORR and clinical outcomes","label":"Cohort 3: Unclassified, papillary, and HL RCC","type":"EXPERIMENTAL"},{"description":"Cohort 4 is an expansion of Cohorts 1+3, which will accure an additional 40 patients","label":"Cohort 4: Unclassified, papillary, and HL RCC","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-08","type":"ESTIMATED"},"conditions":["Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma","Unclassified Renal Cell Carcinoma","Papillary Renal Cell Carcinoma","Fumarate Hydratase Deficient Renal Cell Carcinoma","Succinate Dehydrogenase Deficient Renal Cell Carcinoma","Collecting Duct Renal Cell Carcinoma","Chromophobe Renal Cell Carcinoma"],"enrollment":{"count":60,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"cabozantinib","otherNames":["CABOMETYX®"],"type":"DRUG"},{"name":"nivolumab","otherNames":["Opdivo"],"type":"DRUG"}],"last_update":"2026-09-21","lead_sponsor":"Memorial Sloan Kettering Cancer Center","official_title":"A Phase 2 Open-Label Study of Nivolumab Combined With Cabozantinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (CA209-9KU)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-08","type":"ESTIMATED"},"primary_outcomes":[{"measure":"objective response rate","timeFrame":"2 years"}],"references":[{"citation":"Lee CH, Voss MH, Carlo MI, Chen YB, Zucker M, Knezevic A, Lefkowitz RA, Shapnik N, Dadoun C, Reznik E, Shah NJ, Owens CN, McHugh DJ, Aggen DH, Laccetti AL, Kotecha R, Feldman DR, Motzer RJ. Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates. J Clin Oncol. 2022 Jul 20;40(21):2333-2341. doi: 10.1200/JCO.21.01944. Epub 2022 Mar 17.","pmid":"35298296","type":"DERIVED"}],"start_date":{"date":"2018-08-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma","url":"https://clinicaltrials.gov/study/NCT03635892"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03635892"}